<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2014-05-27" updated="2020-01-02">
  <drugbank-id primary="true">DB08949</drugbank-id>
  <name>Inositol nicotinate</name>
  <description>Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator. It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol. Niacin exists in different forms including nicotinic acid, nicotinamide and other derivatives such as inositol nicotinate. It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate. Nicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent. Inositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon.</description>
  <cas-number>6556-11-2</cas-number>
  <unii>A99MK953KZ</unii>
  <average-mass>810.732</average-mass>
  <monoisotopic-mass>810.19217043</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19549</ref-id>
        <pubmed-id>14986567</pubmed-id>
        <citation>Dib JG, Dedeyan S: Purported benefits of inositol niacinate. Am J Health Syst Pharm. 2004 Feb 1;61(3):307-8.</citation>
      </article>
      <article>
        <ref-id>A19550</ref-id>
        <pubmed-id>23347001</pubmed-id>
        <citation>Milton SG, Robinson K, Ma J, Wei B, Poon IO, Liang D: Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. Xenobiotica. 2013 Sep;43(9):817-22. doi: 10.3109/00498254.2012.762591. Epub 2013  Jan 24.</citation>
      </article>
      <article>
        <ref-id>A19551</ref-id>
        <pubmed-id>15642562</pubmed-id>
        <citation>Canner PL, Furberg CD, Terrin ML, McGovern ME: Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005 Jan 15;95(2):254-7.</citation>
      </article>
      <article>
        <ref-id>A19552</ref-id>
        <pubmed-id>15183629</pubmed-id>
        <citation>Karpe F, Frayn KN: The nicotinic acid receptor--a new mechanism for an old drug. Lancet. 2004 Jun 5;363(9424):1892-4.</citation>
      </article>
      <article>
        <ref-id>A19553</ref-id>
        <pubmed-id>546424</pubmed-id>
        <citation>Harthon L, Brattsand R: Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues. Arzneimittelforschung. 1979;29(12):1859-62.</citation>
      </article>
      <article>
        <ref-id>A19555</ref-id>
        <pubmed-id>18375237</pubmed-id>
        <citation>Kamanna VS, Kashyap ML: Mechanism of action of niacin. Am J Cardiol. 2008 Apr 17;101(8A):20B-26B. doi: 10.1016/j.amjcard.2008.02.029.</citation>
      </article>
      <article>
        <ref-id>A19556</ref-id>
        <pubmed-id>11122723</pubmed-id>
        <citation>Kamanna VS, Kashyap ML: Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2000 Jan;2(1):36-46.</citation>
      </article>
      <article>
        <ref-id>A19558</ref-id>
        <pubmed-id>12873710</pubmed-id>
        <citation>Ganji SH, Kamanna VS, Kashyap ML: Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003 Jun;14(6):298-305.</citation>
      </article>
      <article>
        <ref-id>A19559</ref-id>
        <pubmed-id>27793642</pubmed-id>
        <citation>Garg A, Sharma A, Krishnamoorthy P, Garg J, Virmani D, Sharma T, Stefanini G, Kostis JB, Mukherjee D, Sikorskaya E: Role of Niacin in Current Clinical Practice: A Systematic Review. Am J Med. 2017 Feb;130(2):173-187. doi: 10.1016/j.amjmed.2016.07.038. Epub 2016 Oct 26.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T28</ref-id>
        <isbn>978-0-7020-3471-8</isbn>
        <citation>23. (2012). In Rang and Dale's Pharmacology  (7th ed., pp. 291). Edinburgh: Elsevier/Churchill Livingstone.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L810</ref-id>
        <title>SCIENTIFIC OPINION Inositol hexanicotinate</title>
        <url>http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/949.pdf</url>
      </link>
      <link>
        <ref-id>L842</ref-id>
        <title>Vitamin and Mineral Safety 3rd Edition (2013) Council for Responsible Nutrition (CRN); Niacin: Nicotinic Acid, Nicotinamide, and Inositol Hexanicotinate</title>
        <url>https://www.crnusa.org/sites/default/files/files/resources/13-CRNVMS3-NIACIN.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated as a dietary supplement for the source of niacin. Has been investigated for potential beneficial effects on serum lipids. In Europe, inositol hexanicotinate is indicated as a patented drug known as Hexopal, which is therapeutically indicated for the symptomatic relief of severe intermittent claudication and Raynaud’s phenomenon. </indication>
  <pharmacodynamics>Inositol nicotinate mediates a vasodilatory, lipid-lowering and fibrinolytic effect on the cardiovascular system. Like other niacins, inositol nicotinate is a lipid-regulating agent that reduces the levels of plasma triglycerides, atherogenic apolipoprotein B (apoB)-containing lipoproteins (VLDL, LDL and lipoprotein a) while increasing antiatherogenic apoA-I-containing HDL levels [A19560]. </pharmacodynamics>
  <mechanism-of-action>Inositol nicotinate and other niacins directly and noncompetitively inhibit microsomal enzyme diacylglycerol acyltransferase 2 (DGAT2) responsible for esterification of fatty acids to form triglycerides, resulting in decreased triglyceride synthesis and hepatic atherogenic lipoprotein secretion. Inhibitied triglyceride synthesis results in accelerated intracellular hepatic apo B degradation and the decreased secretion of VLDL and LDL particles [A19555]. Niacin also inhibits hepatic expression of beta-chain adenosine triphosphate synthase which inhibits the removal or uptake of HDL–apo A-I. It is also suggested that niacin increases vascular endothelial cell redox state, resulting in the inhibition of oxidative stress and vascular inflammatory genes or key cytokines involved in atherosclerosis. It acts as a ligand on G-protein coupled receptor 109A (HCAR2/HM74A) and 109B (HCAR3/HM74) which mediates the anti-lipolytic and lipid-lowering effects of nicotinic acid. Niacin-mediated signalling of GPR109A expressed on adipocytes and G(i)-mediated decrease in cAMP levels result in decreased lipolysis, fatty acid mobilization, and triglyceride synthesis. The action of inositol nicotinate on GPR109A expressed on skin and macrophages to cause increased prostaglandin D2/E2 activity is thought to be less significant compared to other niacin molecules as it involves sustained release that leads to less flushing [A19555]. </mechanism-of-action>
  <toxicity>NOAEL is 4000mg. Inositol nicotinate can cause muscle pain, headache, redness of face, nausea, vomiting, edema and rash. </toxicity>
  <metabolism>Inositol nicotinate undergoes hydrolysis by plasma esterases, releasing free nicotinic acid and inositol in a sustained manner. The process takes more than 48hours, where the bloodstream enzymatic hydrolysis of inositol hexanicotinate was found to be slower in the first ester linkage of inositol hexanicotinate than in subsequent linkages [L810]. Sequential hydrolytic steps of inositol nicotinate forms one nicotinic acid molecule in each step, producing eventually six molecules of nicotinic acid and one inositol moiety [A19550]. </metabolism>
  <absorption>Gastrointestinal absorption of inositol hexanicotinate varies widely, with an average of 70% of an orally ingested dose absorbed from stomach and upper small intestines into the bloodstream as intact form. The maximum serum levels of nicotinic acid is reached approximately 6-10 hours after oral ingestion. At low concentrations, the absorption of nicotinic acid and nicotinamide is mediated by sodium ion-dependent facilitated diffusion. At higher concentrations, passive diffusion predominates with doses of 3 to 4 g of niacin being almost completely absorbed [L810]. </absorption>
  <half-life>Mean elimination half life in healthy human adults is approximately one hour [A19550]. </half-life>
  <protein-binding/>
  <route-of-elimination>Unabsorbed inositol nicotinate is detected in feces. </route-of-elimination>
  <volume-of-distribution>Mean Vd following intravenous administration of 50mg/kg of inositol nicotinate in rats is 1051±250 mL/kg [A19550]. </volume-of-distribution>
  <clearance>Mean clearance rate following intravenous administration of 50mg/kg of inositol nicotinate in rats is 65.4±19 mL/min/kg [A19550]. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as hexacarboxylic acids and derivatives. These are carboxylic acids containing exactly six carboxyl groups.</description>
    <direct-parent>Hexacarboxylic acids and derivatives</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Hexacarboxylic acids and derivatives</subclass>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Cyclitols and derivatives</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Pyridinecarboxylic acids</alternative-parent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Cyclitol or derivatives</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hexacarboxylic acid or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Pyridine carboxylic acid</substituent>
    <substituent>Pyridine carboxylic acid or derivatives</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">hexanicotol</synonym>
    <synonym language="english" coder="">Inositol hexanicotinate</synonym>
    <synonym language="english" coder="">Inositol niacinate</synonym>
    <synonym language="english" coder="inn">Inositol nicotinate</synonym>
    <synonym language="english" coder="">mesoinositol hexanicotinate</synonym>
    <synonym language="english" coder="">myo-inositol hexanicotinate</synonym>
  </synonyms>
  <products>
    <product>
      <name>DermaNIC</name>
      <labeller>Allegis Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>28595-500</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-02-03</started-marketing-on>
      <ended-marketing-on>2016-12-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Inositol Nicotinate 250 mg</name>
      <labeller>General Nutrition Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230632</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-11-27</started-marketing-on>
      <ended-marketing-on>2009-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>TL-Care DHA</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-517</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricare Prenatal DHA One</name>
      <labeller>Medecor Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>67112-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricare Prenatal DHA One Rx Multivitamin</name>
      <labeller>Medecor Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>67112-402</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Tricare Prenatal DHA One With Folate</name>
      <labeller>Medecor Pharma, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>67112-302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Hexaniton</name>
      <company>Ni-The</company>
    </international-brand>
    <international-brand>
      <name>Hexazin</name>
      <company>Johnson</company>
    </international-brand>
    <international-brand>
      <name>Hexin</name>
      <company>New Chemical</company>
    </international-brand>
    <international-brand>
      <name>Hexopal</name>
      <company>Clonmel</company>
    </international-brand>
    <international-brand>
      <name>Iexaniton</name>
      <company>Ni-The</company>
    </international-brand>
    <international-brand>
      <name>Nicoxatin</name>
      <company>Fuso Pharmaceutical</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Tricare Prenatal DHA One</name>
      <ingredients>Ascorbic acid + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Doconexent + Docusate + Ferrous fumarate + Fish oil + Folic acid + Icosapent + Inositol nicotinate + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc sulfate</ingredients>
    </mixture>
    <mixture>
      <name>DermaNIC</name>
      <ingredients>Acetylcysteine zinc + Chromium nicotinate + Ferrous cysteine glycinate + Folic acid + Hydroxocobalamin + Inositol nicotinate + Niacin + Nicotinamide</ingredients>
    </mixture>
    <mixture>
      <name>Tricare Prenatal DHA One Rx Multivitamin</name>
      <ingredients>Ascorbic acid + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Doconexent + Docusate + Ferrous fumarate + Fish oil + Folic acid + Icosapent + Inositol nicotinate + Potassium Iodide + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc sulfate</ingredients>
    </mixture>
    <mixture>
      <name>TL-Care DHA</name>
      <ingredients>Ascorbic acid + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Doconexent + Docusate + Ferrous fumarate + Fish oil + Folic acid + Icosapent + Inositol nicotinate + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Tricare Prenatal DHA One With Folate</name>
      <ingredients>Ascorbic acid + Biotin + Cholecalciferol + Cupric sulfate + Cyanocobalamin + Doconexent + Ferrous fumarate + Fish oil + Icosapent + Inositol nicotinate + Levomefolic acid + Potassium Iodide + Pyridoxine + Riboflavin + Thiamine + Vitamin E + Zinc sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Inositol Nicotinate 250 mg</name>
      <ingredients>Inositol + Inositol nicotinate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Nicotinic Acid and Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Other Nutritional Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peripheral Vasodilators</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pyridines</category>
      <mesh-id>D011725</mesh-id>
    </category>
    <category>
      <category>Vasodilating Agents</category>
      <mesh-id>D014665</mesh-id>
    </category>
    <category>
      <category>Vitamin B Complex</category>
      <mesh-id>D014803</mesh-id>
    </category>
    <category>
      <category>Vitamins</category>
      <mesh-id>D014815</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form/>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C04AC03">
      <level code="C04AC">Nicotinic acid and derivatives</level>
      <level code="C04A">PERIPHERAL VASODILATORS</level>
      <level code="C04">PERIPHERAL VASODILATORS</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>88:08.00</ahfs-code>
    <ahfs-code>88:30.00*</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB08949.pdf?1401217307</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>The therapeutic efficacy of Inositol nicotinate can be decreased when used in combination with Patent Blue.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.49</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.74e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.88</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1R,2S,3R,4R,5S,6s)-2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl pyridine-3-carboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(1R,2S,3R,4R,5S,6s)-2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl pyridine-3-carboxylate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>810.732</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>810.19217043</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>O=C(O[C@H]1[C@H](OC(=O)C2=CC=CN=C2)[C@@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@H](OC(=O)C2=CC=CN=C2)[C@@H]1OC(=O)C1=CC=CN=C1)C1=CC=CN=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C42H30N6O12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H/t31-,32-,33-,34+,35-,36-</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>MFZCIDXOLLEMOO-GYSGTQPESA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>235.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>201.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>76.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>18</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>4.02</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Insoluble</value>
      <source>SCIENTIFIC OPINION Inositol hexanicotinate</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>5019</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31699</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3720</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827813</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01813</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>16736141</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Inositol_nicotinate</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1094982</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/international/inositol-nicotinate.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB08949</drugbank-id>
        <name>Inositol nicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01486</drugbank-id>
        <name>Inositol pentanicotinate</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET01486</drugbank-id>
        <name>Inositol pentanicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01487</drugbank-id>
        <name>Inositol tetranicotinate</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET01487</drugbank-id>
        <name>Inositol tetranicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01488</drugbank-id>
        <name>Inositol trinicotinate</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>4</sequence>
      <left-element>
        <drugbank-id>DBMET01488</drugbank-id>
        <name>Inositol trinicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01489</drugbank-id>
        <name>Inositol dinicotinate</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>5</sequence>
      <left-element>
        <drugbank-id>DBMET01489</drugbank-id>
        <name>Inositol dinicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01490</drugbank-id>
        <name>Inositol mononicotinate</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>6</sequence>
      <left-element>
        <drugbank-id>DBMET01490</drugbank-id>
        <name>Inositol mononicotinate</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01491</drugbank-id>
        <name>Inositol</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="3">
      <id>BE0000836</id>
      <name>Hydroxycarboxylic acid receptor 3</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5287</ref-id>
            <pubmed-id>15580557</pubmed-id>
            <citation>Zellner C, Pullinger CR, Aouizerat BE, Frost PH, Kwok PY, Malloy MJ, Kane JP: Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum Mutat. 2005 Jan;25(1):18-21.</citation>
          </article>
          <article>
            <ref-id>A5285</ref-id>
            <pubmed-id>12522134</pubmed-id>
            <citation>Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. Epub 2003 Jan 9.</citation>
          </article>
          <article>
            <ref-id>A11339</ref-id>
            <pubmed-id>12563315</pubmed-id>
            <citation>Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003 Mar;9(3):352-5. Epub 2003 Feb 3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P49019" source="Swiss-Prot">
        <name>Hydroxycarboxylic acid receptor 3</name>
        <general-function>G-protein coupled receptor activity</general-function>
        <specific-function>Receptor for 3-OH-octanoid acid mediates a negative feedback regulation of adipocyte lipolysis to counteract prolipolytic influences under conditions of physiological or pathological increases in beta-oxidation rates. Acts as a low affinity receptor for nicotinic acid. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet.</specific-function>
        <gene-name>HCAR3</gene-name>
        <locus>12q24.31</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>29-50
64-85
103-123
143-163
195-209
237-256
274-298</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.01</theoretical-pi>
        <molecular-weight>44477.93</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:16824</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GPR109B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D10923</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>219867</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>313</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>313</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P49019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HCAR3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>G-protein coupled receptor 109B</synonym>
          <synonym>G-protein coupled receptor HM74</synonym>
          <synonym>G-protein coupled receptor HM74B</synonym>
          <synonym>GPR109B</synonym>
          <synonym>HCA3</synonym>
          <synonym>HM74B</synonym>
          <synonym>Niacin receptor 2</synonym>
          <synonym>NIACR2</synonym>
          <synonym>Nicotinic acid receptor 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010589|Hydroxycarboxylic acid receptor 3
MNRHHLQDHFLEIDKKNCCVFRDDFIAKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK
SSRIFLFNLAVADFLLIICLPFVMDYYVRRSDWKFGDIPCRLVLFMFAMNRQGSIIFLTV
VAVDRYFRVVHPHHALNKISNWTAAIISCLLWGITVGLTVHLLKKKLLIQNGTANVCISF
SICHTFRWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIMVVAIVF
VICFLPSVVVRIHIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVVYYFSSPS
FPNFFSTLINRCLQRKITGEPDNNRSTSVELTGDPNKTRGAPEALIANSGEPWSPSYLGP
TSNNHSKKGHCHQEPASLEKQLGCCIE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010590|Hydroxycarboxylic acid receptor 3 (HCAR3)
ATGAATCGGCACCATCTGCAGGATCACTTTCTGGAAATAGACAAGAAGAACTGCTGTGTG
TTCCGAGATGACTTCATTGCCAAGGTGTTGCCGCCGGTGTTGGGGCTGGAGTTTATCTTT
GGGCTTCTGGGCAATGGCCTTGCCCTGTGGATTTTCTGTTTCCACCTCAAGTCCTGGAAA
TCCAGCCGGATTTTCCTGTTCAACCTGGCAGTAGCTGACTTTCTACTGATCATCTGCCTG
CCGTTCGTGATGGACTACTATGTGCGGCGTTCAGACTGGAAGTTTGGGGACATCCCTTGC
CGGCTGGTGCTCTTCATGTTTGCCATGAACCGCCAGGGCAGCATCATATTCCTCACGGTG
GTGGCGGTAGACAGGTATTTCCGGGTGGTCCATCCCCACCACGCCCTGAACAAGATCTCC
AATTGGACAGCAGCCATCATCTCTTGCCTTCTGTGGGGCATCACTGTTGGCCTAACAGTC
CACCTCCTGAAGAAGAAGTTGCTGATCCAGAATGGCACTGCAAATGTGTGCATCAGCTTC
AGCATCTGCCATACCTTCCGGTGGCACGAAGCTATGTTCCTCCTGGAGTTCTTCCTGCCC
CTGGGCATCATCCTGTTCTGCTCAGCCAGAATTATCTGGAGCCTGCGGCAGAGACAAATG
GACCGGCATGCCAAGATCAAGAGAGCCATCACCTTCATCATGGTGGTGGCCATCGTCTTT
GTCATCTGCTTCCTTCCCAGCGTGGTTGTGCGGATCCACATCTTCTGGCTCCTGCACACT
TCGGGCACGCAGAATTGTGAAGTGTACCGCTCGGTGGACCTGGCGTTCTTTATCACTCTC
AGCTTCACCTACATGAACAGCATGCTGGACCCCGTGGTGTACTACTTCTCCAGCCCATCC
TTTCCCAACTTCTTCTCCACTTTGATCAACCGCTGCCTCCAGAGGAAGATAACAGGTGAG
CCAGATAATAACCGCAGCACGAGCGTCGAGCTCACAGGGGACCCCAACAAAACCAGAGGC
GCTCCAGAGGCGTTAATCGCCAACTCCGGTGAGCCATGGAGCCCCTCTTATCTGGGCCCA
ACCTCAAATAACCATTCCAAGAAGGGACATTGTCACCAAGAACCAGCATCTCTGGAGAAA
CAGTTGGGCTGTTGCATCGAGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000635</id>
      <name>Hydroxycarboxylic acid receptor 2</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5285</ref-id>
            <pubmed-id>12522134</pubmed-id>
            <citation>Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. Epub 2003 Jan 9.</citation>
          </article>
          <article>
            <ref-id>A5287</ref-id>
            <pubmed-id>15580557</pubmed-id>
            <citation>Zellner C, Pullinger CR, Aouizerat BE, Frost PH, Kwok PY, Malloy MJ, Kane JP: Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum Mutat. 2005 Jan;25(1):18-21.</citation>
          </article>
          <article>
            <ref-id>A11339</ref-id>
            <pubmed-id>12563315</pubmed-id>
            <citation>Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003 Mar;9(3):352-5. Epub 2003 Feb 3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q8TDS4" source="Swiss-Prot">
        <name>Hydroxycarboxylic acid receptor 2</name>
        <general-function>Nicotinic acid receptor activity</general-function>
        <specific-function>Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid &gt; acifran &gt; 5-methyl nicotinic acid = acipimox &gt;&gt; nicotinuric acid = nicotinamide.</specific-function>
        <gene-name>HCAR2</gene-name>
        <locus>12q24.31</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>34-54
64-84
103-123
143-163
193-213
230-250
274-294</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.37</theoretical-pi>
        <molecular-weight>41849.08</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:24827</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GPR109A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AY148884</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28975188</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>312</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>312</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8TDS4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HCAR2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>G-protein coupled receptor 109A</synonym>
          <synonym>G-protein coupled receptor HM74A</synonym>
          <synonym>GPR109A</synonym>
          <synonym>HCA2</synonym>
          <synonym>HM74A</synonym>
          <synonym>Niacin receptor 1</synonym>
          <synonym>NIACR1</synonym>
          <synonym>Nicotinic acid receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010442|Hydroxycarboxylic acid receptor 2
MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWK
SSRIFLFNLAVADFLLIICLPFLMDNYVRRWDWKFGDIPCRLMLFMLAMNRQGSIIFLTV
VAVDRYFRVVHPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKMPIQNGGANLCSSF
SICHTFQWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIMVVAIVF
VICFLPSVVVRIRIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVVYYFSSPS
FPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPWSPSYLGP
TSP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010443|Hydroxycarboxylic acid receptor 2 (HCAR2)
ATGAATCGGCACCATCTGCAGGATCACTTTCTGGAAATAGACAAGAAGAACTGCTGTGTG
TTCCGAGATGACTTCATTGTCAAGGTGTTGCCGCCGGTGTTGGGGCTGGAGTTTATCTTC
GGGCTTCTGGGCAATGGCCTTGCCCTGTGGATTTTCTGTTTCCACCTCAAGTCCTGGAAA
TCCAGCCGGATTTTCCTGTTCAACCTGGCAGTGGCTGACTTTCTACTGATCATCTGCCTG
CCCTTCCTGATGGACAACTATGTGAGGCGTTGGGACTGGAAGTTTGGGGACATCCCTTGC
CGGCTGATGCTCTTCATGTTGGCTATGAACCGCCAGGGCAGCATCATCTTCCTCACGGTG
GTGGCGGTAGACAGGTATTTCCGGGTGGTCCATCCCCACCACGCCCTGAACAAGATCTCC
AATCGGACAGCAGCCATCATCTCTTGCCTTCTGTGGGGCATCACTATTGGCCTGACAGTC
CACCTCCTGAAGAAGAAGATGCCGATCCAGAATGGCGGTGCAAATTTGTGCAGCAGCTTC
AGCATCTGCCATACCTTCCAGTGGCACGAAGCCATGTTCCTCCTGGAGTTCTTCCTGCCC
CTGGGCATCATCCTGTTCTGCTCAGCCAGAATTATCTGGAGCCTGCGGCAGAGACAAATG
GACCGGCATGCCAAGATCAAGAGAGCCATCACCTTCATCATGGTGGTGGCCATCGTCTTT
GTCATCTGCTTCCTTCCCAGCGTGGTTGTGCGGATCCGCATCTTCTGGCTCCTGCACACT
TCGGGCACGCAGAATTGTGAAGTGTACCGCTCGGTGGACCTGGCGTTCTTTATCACTCTC
AGCTTCACCTACATGAACAGCATGCTGGACCCCGTGGTGTACTACTTCTCCAGCCCATCC
TTTCCCAACTTCTTCTCCACTTTGATCAACCGCTGCCTCCAGAGGAAGATGACAGGTGAG
CCAGATAATAACCGCAGCACGAGCGTCGAGCTCACAGGGGACCCCAACAAAACCAGAGGC
GCTCCAGAGGCGTTAATGGCCAACTCCGGTGAGCCATGGAGCCCCTCTTATCTGGGCCCA
ACCTCTCCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>nicotinic acid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of adiponectin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neutrophil apoptotic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="2">
      <id>BE0003841</id>
      <name>ATP synthase subunit beta, mitochondrial</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19557</ref-id>
            <pubmed-id>18316796</pubmed-id>
            <citation>Zhang LH, Kamanna VS, Zhang MC, Kashyap ML: Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res. 2008 Jun;49(6):1195-201. doi: 10.1194/jlr.M700426-JLR200. Epub 2008  Mar 3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P06576" source="Swiss-Prot">
        <name>ATP synthase subunit beta, mitochondrial</name>
        <general-function>Transporter activity</general-function>
        <specific-function>Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Subunits alpha and beta form the catalytic core in F(1). Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits.</specific-function>
        <gene-name>ATP5B</gene-name>
        <locus>12q13.13</locus>
        <cellular-location>Mitochondrion</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.07</theoretical-pi>
        <molecular-weight>56559.42</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:830</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X03559</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28940</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06576</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ATPB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.14</synonym>
          <synonym>ATPMB</synonym>
          <synonym>ATPSB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012680|ATP synthase subunit beta, mitochondrial
MLGFVGRVAAAPASGALRRLTPSASLPPAQLLLRAAPTAVHPVRDYAAQTSPSPKAGAAT
GRIVAVIGAVVDVQFDEGLPPILNALEVQGRETRLVLEVAQHLGESTVRTIAMDGTEGLV
RGQKVLDSGAPIKIPVGPETLGRIMNVIGEPIDERGPIKTKQFAPIHAEAPEFMEMSVEQ
EILVTGIKVVDLLAPYAKGGKIGLFGGAGVGKTVLIMELINNVAKAHGGYSVFAGVGERT
REGNDLYHEMIESGVINLKDATSKVALVYGQMNEPPGARARVALTGLTVAEYFRDQEGQD
VLLFIDNIFRFTQAGSEVSALLGRIPSAVGYQPTLATDMGTMQERITTTKKGSITSVQAI
YVPADDLTDPAPATTFAHLDATTVLSRAIAELGIYPAVDPLDSTSRIMDPNIVGSEHYDV
ARGVQKILQDYKSLQDIIAILGMDELSEEDKLTVSRARKIQRFLSQPFQVAEVFTGHMGK
LVPLKETIKGFQQILAGEYDHLPEQAFYMVGPIEEAVAKADKLAEEHSS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012681|ATP synthase subunit beta, mitochondrial (ATP5B)
ATGTTGGGGTTTGTGGGTCGGGTGGCCGCTGCTCCGGCCTCCGGGGCCTTGCGGAGACTC
ACCCCTTCAGCGTCGCTGCCCCCAGCTCAGCTCTTACTGCGGGCCGCTCCGACGGCGGTC
CATCCTGTCAGGGACTATGCGGCGCAAACATCTCCTTCGCCAAAAGCAGGCGCCGCCACC
GGGCGCATCGTGGCGGTCATTGGCGCAGTGGTGGACGTCCAGTTTGATGAGGGACTACCA
CCAATTCTAAATGCCCTGGAAGTGCAAGGCAGGGAGACCAGACTGGTTTTGGAGGTGGCC
CAGCATTTGGGTGAGAGCACAGTAAGGACTATTGCTATGGATGGTACAGAAGGCTTGGTT
AGAGGCCAGAAAGTACTGGATTCTGGTGCACCAATCAAAATTCCTGTTGGTCCTGAGACT
TTGGGCAGAATCATGAATGTCATTGGAGAACCTATTGATGAAAGAGGTCCCATCAAAACC
AAACAATTTGCTCCCATTCATGCTGAGGCTCCAGAGTTCATGGAAATGAGTGTTGAGCAG
GAAATTCTGGTGACTGGTATCAAGGTTGTCGATCTGCTAGCTCCCTATGCCAAGGGTGGC
AAAATTGGGCTTTTTGGTGGTGCTGGAGTTGGCAAGACTGTACTGATCATGGAGTTAATC
AACAATGTCGCCAAAGCCCATGGTGGTTACTCTGTGTTTGCTGGTGTTGGTGAGAGGACC
CGTGAAGGCAATGATTTATACCATGAAATGATTGAATCTGGTGTTATCAACTTAAAAGAT
GCCACCTCTAAGGTAGCGCTGGTATATGGTCAAATGAATGAACCACCTGGTGCTCGTGCC
CGGGTAGCTCTGACTGGGCTGACTGTGGCTGAATACTTCAGAGACCAAGAAGGTCAAGAT
GTACTGCTATTTATTGATAACATCTTTCGCTTCACCCAGGCTGGTTCAGAGGTGTCTGCA
TTATTGGGCCGAATCCCTTCTGCTGTGGGCTATCAGCCTACCCTGGCCACTGACATGGGT
ACTATGCAGGAAAGAATTACCACTACCAAGAAGGGATCTATCACCTCTGTACAGGCTATC
TATGTGCCTGCTGATGACTTGACTGACCCTGCCCCTGCTACTACGTTTGCCCATTTGGAT
GCTACCACTGTACTGTCGCGTGCCATTGCTGAGCTGGGCATCTATCCAGCTGTGGATCCT
CTAGACTCCACCTCTCGTATCATGGATCCCAACATTGTTGGCAGTGAGCATTACGATGTT
GCCCGTGGGGTGCAAAAGATCCTGCAGGACTACAAATCCCTCCAGGATATCATTGCCATC
CTGGGTATGGATGAACTTTCTGAGGAAGACAAGTTGACCGTGTCCCGTGCACGGAAAATA
CAGCGTTTCTTGTCTCAGCCATTCCAGGTTGCTGAGGTCTTCACAGGTCATATGGGGAAG
CTGGTACCCCTGAAGGAGACCATCAAAGGATTCCAGCAGATTTTGGCAGGTGAATATGAC
CATCTCCCAGAACAGGCCTTCTATATGGTGGGACCCATTGAAGAAGCTGTGGCAAAAGCT
GATAAGCTGGCTGAAGAGCATTCATCGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00006</identifier>
            <name>ATP-synt_ab</name>
          </pfam>
          <pfam>
            <identifier>PF00306</identifier>
            <name>ATP-synt_ab_C</name>
          </pfam>
          <pfam>
            <identifier>PF02874</identifier>
            <name>ATP-synt_ab_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial nucleoid</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial proton-transporting ATP synthase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial proton-transporting ATP synthase, catalytic core</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MHC class I protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>proton-transporting ATP synthase activity, rotational mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>proton-transporting ATPase activity, rotational mechanism</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ATP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ATP hydrolysis coupled proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>generation of precursor metabolites and energy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrial ATP synthesis coupled proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitochondrion organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell adhesion involved in substrate-bound cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organelle organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proton transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of intracellular pH</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory electron transport chain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
    <enzyme position="5">
      <id>BE0008719</id>
      <name>Diacylglycerol O-acyltransferase 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19560</ref-id>
            <pubmed-id>15258194</pubmed-id>
            <citation>Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML: Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004 Oct;45(10):1835-45. Epub 2004 Jul 16.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q96PD7" source="Swiss-Prot">
        <name>Diacylglycerol O-acyltransferase 2</name>
        <general-function>Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Functions also as an acyl-CoA retinol acyltransferase (ARAT).</general-function>
        <specific-function>2-acylglycerol o-acyltransferase activity</specific-function>
        <gene-name>DGAT2</gene-name>
        <locus>11q13.5</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>70-88
93-112</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>43830.475</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:16940</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q96PD7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DGAT2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.3.1.20</synonym>
          <synonym>Acyl-CoA retinol O-fatty-acyltransferase</synonym>
          <synonym>ARAT</synonym>
          <synonym>Diglyceride acyltransferase 2</synonym>
          <synonym>Retinol O-fatty-acyltransferase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049585|Diacylglycerol O-acyltransferase 2
MKTLIAAYSGVLRGERQAEADRSQRSHGGPALSREGSGRWGTGSSILSALQDLFSVTWLN
RSKVEKQLQVISVLQWVLSFLVLGVACSAILMYIFCTDCWLIAVLYFTWLVFDWNTPKKG
GRRSQWVRNWAVWRYFRDYFPIQLVKTHNLLTTRNYIFGYHPHGIMGLGAFCNFSTEATE
VSKKFPGIRPYLATLAGNFRMPVLREYLMSGGICPVSRDTIDYLLSKNGSGNAIIIVVGG
AAESLSSMPGKNAVTLRNRKGFVKLALRHGADLVPIYSFGENEVYKQVIFEEGSWGRWVQ
KKFQKYIGFAPCIFHGRGLFSSDTWGLVPYSKPITTVVGEPITIPKLEHPTQQDIDLYHT
MYMEALVKLFDKHKTKFGLPETEVLEVN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049586|Diacylglycerol O-acyltransferase 2 (DGAT2)
ATGAAGACCCTCATAGCCGCCTACTCCGGGGTCCTGCGCGGCGAGCGTCAGGCCGAGGCT
GACCGGAGCCAGCGCTCTCACGGAGGACCTGCGCTGTCGCGCGAGGGGTCTGGGAGATGG
GGCACTGGATCCAGCATCCTCTCCGCCCTCCAGGACCTCTTCTCTGTCACCTGGCTCAAT
AGGTCCAAGGTGGAAAAGCAGCTACAGGTCATCTCAGTGCTCCAGTGGGTCCTGTCCTTC
CTTGTACTGGGAGTGGCCTGCAGTGCCATCCTCATGTACATATTCTGCACTGATTGCTGG
CTCATCGCTGTGCTCTACTTCACTTGGCTGGTGTTTGACTGGAACACACCCAAGAAAGGT
GGCAGGAGGTCACAGTGGGTCCGAAACTGGGCTGTGTGGCGCTACTTTCGAGACTACTTT
CCCATCCAGCTGGTGAAGACACACAACCTGCTGACCACCAGGAACTATATCTTTGGATAC
CACCCCCATGGTATCATGGGCCTGGGTGCCTTCTGCAACTTCAGCACAGAGGCCACAGAA
GTGAGCAAGAAGTTCCCAGGCATACGGCCTTACCTGGCTACACTGGCAGGCAACTTCCGA
ATGCCTGTGTTGAGGGAGTACCTGATGTCTGGAGGTATCTGCCCTGTCAGCCGGGACACC
ATAGACTATTTGCTTTCAAAGAATGGGAGTGGCAATGCTATCATCATCGTGGTCGGGGGT
GCGGCTGAGTCTCTGAGCTCCATGCCTGGCAAGAATGCAGTCACCCTGCGGAACCGCAAG
GGCTTTGTGAAACTGGCCCTGCGTCATGGAGCTGACCTGGTTCCCATCTACTCCTTTGGA
GAGAATGAAGTGTACAAGCAGGTGATCTTCGAGGAGGGCTCCTGGGGCCGATGGGTCCAG
AAGAAGTTCCAGAAATACATTGGTTTCGCCCCATGCATCTTCCATGGTCGAGGCCTCTTC
TCCTCCGACACCTGGGGGCTGGTGCCCTACTCCAAGCCCATCACCACTGTTGTGGGAGAG
CCCATCACCATCCCCAAGCTGGAGCACCCAACCCAGCAAGACATCGACCTGTACCACACC
ATGTACATGGAGGCCCTGGTGAAGCTCTTCGACAAGCACAAGACCAAGTTCGGCCTCCCG
GAGACTGAGGTCCTGGAGGTGAACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03982</identifier>
            <name>DAGAT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lipid particle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>2-acylglycerol O-acyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>diacylglycerol O-acyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinol O-fatty-acyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acylglycerol acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to oleic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular triglyceride homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diacylglycerol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fat pad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycerol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid storage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-chain fatty-acyl-CoA metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>low-density lipoprotein particle clearance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fatty acid oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gluconeogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of triglyceride biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of plasma lipoprotein particle levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>triglyceride biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="1">
      <id>BE0004708</id>
      <name>Sodium-coupled monocarboxylate transporter 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A956</ref-id>
            <pubmed-id>15651982</pubmed-id>
            <citation>Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q8N695" source="Swiss-Prot">
        <name>Sodium-coupled monocarboxylate transporter 1</name>
        <general-function>Symporter activity</general-function>
        <specific-function>Acts as an electrogenic sodium (Na(+)) and chloride (Cl-)-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactate, pyruvate, acetate, propionate, valerate and butyrate), lactate, mocarboxylate drugs (nicotinate, benzoate, salicylate and 5-aminosalicylate) and ketone bodies (beta-D-hydroxybutyrate, acetoacetate and alpha-ketoisocaproate), with a Na(+):substrate stoichiometry of between 4:1 and 2:1. Catalyzes passive carrier mediated diffusion of iodide. Mediates iodide transport from the thyrocyte into the colloid lumen through the apical membrane. May be responsible for the absorption of D-lactate and monocarboxylate drugs from the intestinal tract. Acts as a tumor suppressor, suppressing colony formation in colon cancer, prostate cancer and glioma cell lines. May play a critical role in the entry of L-lactate and ketone bodies into neurons by a process driven by an electrochemical Na(+) gradient and hence contribute to the maintenance of the energy status and function of neurons.</specific-function>
        <gene-name>SLC5A8</gene-name>
        <locus/>
        <cellular-location>Apical cell membrane</cellular-location>
        <transmembrane-regions>10-30
52-72
84-104
133-153
162-182
190-210
240-260
280-300
337-359
390-410
416-436
440-460
519-539</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>66577.005</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:19119</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>922</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8N695</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SC5A8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AIT</synonym>
          <synonym>Apical iodide transporter</synonym>
          <synonym>Electrogenic sodium monocarboxylate cotransporter</synonym>
          <synonym>SMCT</synonym>
          <synonym>SMCT1</synonym>
          <synonym>Sodium iodide-related cotransporter</synonym>
          <synonym>Solute carrier family 5 member 8</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013272|Sodium-coupled monocarboxylate transporter 1
MDTPRGIGTFVVWDYVVFAGMLVISAAIGIYYAFAGGGQQTSKDFLMGGRRMTAVPVALS
LTASFMSAVTVLGTPSEVYRFGAIFSIFAFTYFFVVVISAEVFLPVFYKLGITSTYEYLE
LRFNKCVRLCGTVLFIVQTILYTGIVIYAPALALNQVTGFDLWGAVVATGVVCTFYCTLG
GLKAVIWTDVFQVGIMVAGFASVIIQAVVMQGGISTILNDAYDGGRLNFWNFNPNPLQRH
TFWTIIIGGTFTWTSIYGVNQSQVQRYISCKSRFQAKLSLYINLVGLWAILTCSVFCGLA
LYSRYHDCDPWTAKKVSAPDQLMPYLVLDILQDYPGLPGLFVACAYSGTLSTVSSSINAL
AAVTVEDLIKPYFRSLSERSLSWISQGMSVVYGALCIGMAALASLMGALLQAALSVFGMV
GGPLMGLFALGILVPFANSIGALVGLMAGFAISLWVGIGAQIYPPLPERTLPLHLDIQGC
NSTYNETNLMTTTEMPFTTSVFQIYNVQRTPLMDNWYSLSYLYFSTVGTLVTLLVGILVS
LSTGGRKQNLDPRYILTKEDFLSNFDIFKKKKHVLSYKSHPVEDGGTDNPAFNHIELNSD
QSGKSNGTRL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013273|Sodium-coupled monocarboxylate transporter 1 (SLC5A8)
ATGGACACGCCACGGGGCATCGGCACCTTCGTGGTGTGGGACTACGTGGTGTTCGCGGGC
ATGCTGGTCATCTCGGCCGCCATCGGCATCTACTACGCCTTCGCTGGGGGCGGCCAGCAG
ACCTCCAAGGACTTCCTGATGGGCGGCCGCAGAATGACCGCAGTGCCCGTGGCGCTGTCC
CTCACCGCTAGCTTCATGTCAGCCGTCACTGTCCTGGGCACCCCCTCCGAGGTCTACCGT
TTTGGGGCCATTTTTAGCATCTTTGCCTTCACCTACTTCTTTGTGGTGGTCATCAGCGCG
GAGGTCTTCCTCCCGGTGTTCTACAAACTGGGAATTACCAGCACCTACGAGTATTTAGAA
CTTCGATTTAACAAATGTGTTCGTCTCTGTGGAACAGTCCTCTTCATTGTTCAAACAATT
CTGTATACTGGAATTGTTATTTATGCCCCTGCCCTGGCTTTGAATCAAGTCACAGGATTT
GATCTGTGGGGCGCGGTAGTGGCAACGGGGGTGGTCTGCACATTCTACTGCACACTGGGT
GGTCTTAAAGCAGTTATCTGGACAGATGTTTTTCAAGTTGGGATCATGGTGGCTGGATTT
GCATCCGTGATTATACAGGCTGTGGTGATGCAAGGTGGAATCAGCACTATTTTAAATGAT
GCCTATGATGGTGGAAGATTAAATTTCTGGAATTTTAATCCTAACCCTTTGCAAAGACAC
ACCTTCTGGACAATTATTATAGGAGGGACCTTCACATGGACCAGCATCTACGGTGTCAAC
CAATCCCAGGTGCAGAGATATATTTCTTGTAAAAGCAGATTCCAGGCAAAACTGTCTCTC
TACATCAATCTTGTGGGACTCTGGGCAATCCTCACATGCTCAGTGTTTTGTGGGCTCGCC
CTATATTCCAGGTACCATGACTGTGATCCTTGGACAGCCAAGAAAGTGTCTGCACCAGAC
CAGCTCATGCCTTATTTGGTACTGGACATTCTGCAAGATTATCCAGGACTTCCTGGACTT
TTTGTGGCCTGTGCTTACAGTGGGACATTAAGCACAGTGTCCTCCAGTATTAATGCCTTA
GCAGCAGTAACTGTGGAAGATCTAATCAAACCTTACTTCAGATCGCTCTCAGAAAGGTCT
CTGTCTTGGATTTCCCAAGGAATGAGTGTGGTGTATGGAGCCCTGTGTATTGGAATGGCT
GCGCTGGCGTCACTTATGGGAGCTTTGTTGCAGGCAGCACTCAGCGTATTTGGTATGGTT
GGTGGACCACTTATGGGCCTGTTCGCTTTGGGCATTTTGGTTCCCTTTGCCAACTCAATT
GGAGCACTTGTTGGTCTGATGGCTGGATTTGCCATTTCTCTATGGGTTGGAATTGGAGCT
CAAATATATCCTCCACTTCCTGAGAGAACATTGCCATTGCACCTTGATATCCAAGGCTGT
AACAGCACCTACAATGAGACAAATTTGATGACAACCACAGAAATGCCATTTACTACTAGT
GTTTTTCAAATATACAATGTTCAAAGGACTCCACTGATGGATAACTGGTATTCTTTATCA
TATCTGTACTTCAGCACTGTTGGAACTTTGGTAACATTATTAGTGGGGATACTTGTCAGT
TTATCAACAGGAGGAAGAAAACAGAACTTAGACCCCAGATACATACTAACCAAAGAGGAC
TTTTTATCCAATTTTGATATTTTTAAGAAAAAGAAGCATGTTTTGAGCTATAAATCACAT
CCAGTGGAAGATGGTGGAACTGATAATCCTGCTTTCAACCACATTGAATTGAACTCAGAT
CAGAGTGGCAAGAGCAATGGGACTCGTTTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00474</identifier>
            <name>SSF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>symporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>